In addition, HIF2α has been shown to be constitutively activated in paragangliomas with VHL mutations [40, 41]; accordingly, such tumors were also shown to harbor mutations associated with unregulated activity of HIF2α [13, 42–44]. The gene discussed is EPAS1; the disease is paraganglioma.